InvestorsHub Logo
Followers 12
Posts 1261
Boards Moderated 0
Alias Born 04/12/2011

Re: None

Tuesday, 07/25/2017 2:00:13 PM

Tuesday, July 25, 2017 2:00:13 PM

Post# of 236
Up 17% . Just nailed the patent on our lead immune-onco drug.
"COM701 is a humanized hybridoma antibody that binds with high affinity to PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen, blocking its interaction with PVRL2. Blockade of PVRIG by COM701 has demonstrated potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses. In addition, COM701 combined with antagonist anti-TIGIT or anti-PD1 antibodies has demonstrated synergistic effect on human T cell stimulation, indicating the potential of these combinations to further enhance immune response against tumors."
And we've got at least a dozen more in the works.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CGEN News